- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03872414
Emotion Study/Substudy: Flexible Brain Study
Emotion Study (Improving Neural Dysregulation in Advanced Age: A Neurofeedback Approach)/Substudy: Flexible Brain Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
There is increasing evidence that age-related alterations in brain function associated with affective processing and attention contribute to these motivational and emotional changes with age.
Based on these theoretical considerations as well as the previous study's data, the proposed research will apply well-tested emotion processing and attention paradigms to address the pivotal question of whether brain activity can be modulated in healthy aging and PD (in the substudy) via contingent rt-fMRI neurofeedback and whether this neuroregulatory modulation increases emotion processing and cognitive performance.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Ebner Lab
- Phone Number: 352-273-2141
- Email: Psy-ebnerlab@psych.ufl.edu
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32611-2250
- University of Florida
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria: Young adults
- aged 18-35 years of age
- native English speaker
- at least 8th grade education
- generally physically and neurologically healthy as determined by the Health Demographics Screener
- eligible for MRI as determined by the MRI Eligibility Interview (including not being pregnant)
- scores within normal limits on a cognitive screener (MoCA)
- no indication of serious psychiatric disturbance including major depression (based on Mental Health Screener)
- willing and able to give informed consent
Inclusion Criteria: Older adults
- age 55-100 years of age
- native English speaker
- at least 8th grade education
- generally physically and neurologically healthy as determined by the Health Demographics Screener
- eligible for MRI as determined by the MRI Eligibility Interview
- no indication of dementia based on score of 30 or above on the Telephone Interview for Cognitive Status and nonimpaired score on the Montreal Cognitive Assessment (MoCA -- score of 22 and above)
- no indication of serious psychiatric disturbance including current major depression (based on Mental Health Screener)
- willing and able to give informed consent
Inclusion Criteria: Parkinson patients
- must meet criteria for diagnosis of idiopathic Parkinson disease according the UK Brain Bank by a movement trained neurologist.
- age 55-100 years of age
- native English speaker
- at least 8th grade education
- generally physically and neurologically healthy other than Parkinson disease
- eligible for MRI as determined by the MRI Eligibility Interview
- no indication of dementia based on cognitive screening measures (TICS -- score of 30 or above, and MoCa -- score of 22 and above)
- no indication of serious psychiatric disturbance including current major depression
- willing and able to give informed consent
Inclusion Criteria: Individuals with SCD and a family history of dementia or Alzheimer's disease
- age 55-100 years of age
- native English speaker
- at least 8th grade education
- generally physically and neurologically healthy as determined by the Health Demographics Screener
- eligible for MRI as determined by the MRI Eligibility Interview
- no indication of dementia based on score of 30 or above on the Telephone Interview for Cognitive Status and nonimpaired score on the Montreal Cognitive Assessment (MoCA -- score of 22 and above)
- no indication of serious psychiatric disturbance including current major depression (based on Mental Health Screener)
- willing and able to give informed consent
- community-dwelling with subjective report of cognitive complaints with scores >16 on the Cognitive Change Index (CCI-20)
- no evidence of dementia or mild cognitive impairment based on cognitive screening using the MoCA; scores must fall within normal limits for age, education, and sex
- no psychometric evidence of neuropsychological impairment on a modified Neuropsychological Battery from the NACC Unified Data Set, version 3
- score of 0 on the Global Clinic Dementia Rating (CDR) scale
- normal functional behavior in terms of daily activities, based on the Functional Activities Scale (FAQ)
- availability of an informant (over the phone) who can provide information about the participant's complaints using the informant version of the CCI-20, and corroborate normal activities of daily living on the FAQ and the CDR scale.
Exclusion Criteria:
- Pregnant or possibly pregnant
- Claustrophobia
- Large pieces of metal in the body, particularly in the face and neck.
- Piercings or metal implants that cannot be removed from the body
- Surgery on the brain or any prior serious brain damage or disease
- Dementia or severe cognitive disorders
- use of antipsychotics, sedatives, or other medications with significant anticholinergic properties (due to potential influence on memory)
- use of prescribed 'memory enhancing' medications such as Aricept or Namenda.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Healthy Younger Group
Participants will receive rt-fMRI training to increase anterior cingulate cortex activation.
|
Functional Magnetic Resonance Imaging Participants in the experimental group will be trained using functional magnetic resonance imaging to regulation brain activity in anterior cingulate cortex. The anterior cingulate cortex is a brain region that is known to be involved in emotion processing. Activation of this region is expected to improve emotion processing. |
Experimental: Healthy Older Group
Participants will receive rt-fMRI training to increase anterior cingulate cortex activation.
|
Functional Magnetic Resonance Imaging Participants in the experimental group will be trained using functional magnetic resonance imaging to regulation brain activity in anterior cingulate cortex. The anterior cingulate cortex is a brain region that is known to be involved in emotion processing. Activation of this region is expected to improve emotion processing. |
Experimental: Parkinson Disease Group
Participants will receive rt-fMRI training to increase anterior cingulate cortex activation.
|
Functional Magnetic Resonance Imaging Participants in the experimental group will be trained using functional magnetic resonance imaging to regulation brain activity in anterior cingulate cortex. The anterior cingulate cortex is a brain region that is known to be involved in emotion processing. Activation of this region is expected to improve emotion processing. |
Active Comparator: Control Group
Participants will receive rt-fMRI training to increase primary auditory cortex activation.
|
Functional Magnetic Resonance Imaging Participants in each group will be trained using functional magnetic resonance imaging to regulation brain activity in primary auditory cortex.
The primary auditory cortex is a brain region that is NOT specifically involved in emotion processing.
Activation of this region is NOT expected to improve emotion processing; and thus activation of this brain region serves as "control/placebo" condition in the current design (placebo comparator).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in BOLD signal response
Time Frame: Baseline; Day 8
|
Change in blood-oxygen-level dependent (BOLD) signal response of the anterior cingulate cortex.
|
Baseline; Day 8
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Natalie Ebner, PhD, University of Florida, Department of Psychology
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB201300814-PD -N
- UL1TR001427 (U.S. NIH Grant/Contract)
- 1R21AG057200 (U.S. NIH Grant/Contract)
- 20A15 (Other Identifier: Ed and Ethel Moore Alzheimer's Disease Research Program)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on Anterior cingulate cortex activation
-
Stanford UniversityCompletedDepression and SuicideUnited States
-
University of California, Los AngelesRecruiting
-
University of FloridaCompleted
-
Hacettepe UniversityStanford University; St. Marianna University School of MedicineCompletedActivation of Primordial FolliclesTurkey
-
Federal University of Health Science of Porto AlegreDouglas HaselstromCompleted
-
Baylor College of MedicineCompletedHyperglycemia | Diabetes MellitusUnited States
-
CONRADCompletedVaginal Infections | Vaginal InflammationUnited States